A0088 - Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients.

MLA

Morra, S., et al. “A0088 - Survival Benefit of Nephroureterectomy in Systemic Therapy Exposed Metastatic Upper Tract Urinary Urothelial Carcinoma Patients.” European Urology, vol. 85, Mar. 2024, p. S793. EBSCOhost, https://doi.org/10.1016/S0302-2838(24)00668-7.

APA

Morra, S., Incesu, R. B., Scheipner, L., Baudo, A., Jannello, L. M. I., Siech, C., De Angelis, M., Tian, Z., Califano, G., Colla’ Ruvolo, C., Creta, M., Saad, F., Shariat, S., Chun, F., De Cobelli, O., Musi, G., Briganti, A., Tilki, D., Ahyai, S., & Carmignani, L. (2024). A0088 - Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients. European Urology, 85, S793. https://doi.org/10.1016/S0302-2838(24)00668-7

Chicago

Morra, S., R.B. Incesu, L. Scheipner, A. Baudo, L.M.I. Jannello, C. Siech, M. De Angelis, et al. 2024. “A0088 - Survival Benefit of Nephroureterectomy in Systemic Therapy Exposed Metastatic Upper Tract Urinary Urothelial Carcinoma Patients.” European Urology 85 (March): S793. doi:10.1016/S0302-2838(24)00668-7.